慶應義塾研究者情報データベース

学歴 【 表示 ／ 非表示 】

学歴 【 表示 ／ 非表示 】

• 1986年03月

  共立薬科大学, 薬学部

  大学, 卒業

学位 【 表示 ／ 非表示 】

学位 【 表示 ／ 非表示 】

• 博士（薬学）, 共立薬科大学, 論文, 2007年12月

研究分野 【 表示 ／ 非表示 】

研究分野 【 表示 ／ 非表示 】

• 化学系薬学

• 創薬化学

研究テーマ 【 表示 ／ 非表示 】

研究テーマ 【 表示 ／ 非表示 】

• パーキンソン病治療薬の創製, 

  2012年

  -

  継続中

• 抗酸化活性化合物の合成とデザイン, 

  2002年04月

  -

  継続中

著書 【 表示 ／ 非表示 】

著書 【 表示 ／ 非表示 】

• Interprofessional Education at the Keio University Faculty of Pharmacy, in: Advanced Initiatives in Interprofessional Education in Japan" (ed. by Watanabe H, Koizumi M)."

  Ehara Y, Abe Y, Fujimoto K, Fukushima N, Iijima S, Ishikawa S, Kishimoto K, Mochizuki M, Takahashi K, Yokota E, Kobayashi S., Springer, Tokyo, Berlin, Heidelberg, New York, 2010年02月

  担当範囲: pp57-63

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• Synthesis and antitumor activity of novel pyridinium fullerene derivatives

  Yasuno T., Ohe T., Ikeda H., Takahashi K., Nakamura S., Mashino T.

  International Journal of Nanomedicine （International Journal of Nanomedicine)  14   6325 - 6337 2019年

  ISSN  11769114

  　概要を見る

  © 2019 Yasuno et al. Purpose: We have previously reported that some cationic fullerene derivatives exhibited anticancer activity, and they are expected to be a potential lead compound for an anti-drug resistant cancer agent. However, they are bis-adducts and a mixture of multiple regioisomers, which cannot be readily separated due to the variability of substituent positions on the fullerene cage. To overcome this issue, we evaluated the antiproliferative activities of a set of mono-adduct derivatives and examined their structure-activity relationship. In addition, the in vivo antitumor activity of selected derivatives was also examined. Methods: Nineteen pyridinium fullerene derivatives were newly designed and synthesized in this study. Their antiproliferative activities were evaluated using several cancer cell lines including drug-resistant cells. Furthermore, in vivo antitumor activity of several derivatives was investigated in mouse xenograft model of human lung cancer. Results: The derivatives inhibited the proliferation of cancer cell lines, including cisplatin-resistant cells and doxorubicin-resistant cells. It was also shown that compound 10 (10 μM), 13 (10 μM) and cis-14 (10 μM) induced the intracellular oxidative stress. In addition, compound 13 (20 mg/kg) and cis-14 (15 mg/kg) significantly exhibited antitumor activity in mouse xenograft model of human lung cancer. Conclusion: We synthesized a novel set of mono-adduct fullerene derivatives functionalized with pyridinium groups and found that most of them show potent antiproliferative activities against cancer cell lines and some of them show significant antitumor activities in vivo. We propose that these fullerene derivatives serve as the lead compounds for a novel type of antitumor agents.

  • Access to Document (DOI)

• Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation

  Ohe T., Umezawa R., Kitagawara Y., Yasuda D., Takahashi K., Nakamura S., Abe A., Sekine S., Ito K., Okunushi K., Morio H., Furihata T., Anzai N., Mashino T.

  Bioorganic and Medicinal Chemistry Letters （Bioorganic and Medicinal Chemistry Letters)  28 （ 23-24 ） 3708 - 3711 2018年12月

  ISSN  0960894X

  　概要を見る

  © 2018 Elsevier Ltd We synthesized six novel BBR derivatives that were designed to avoid metabolic activation via ipso-substitution and evaluated for their degree of toxicity and hURAT1 inhibition. It was found that all of the derivatives demonstrate lower cytotoxicity in mouse hepatocytes and lower levels of metabolic activation than BBR, while maintaining their inhibitory activity toward the uric acid transporter. We propose that these derivatives could serve as effective uricosuric agents that have much better safety profiles than BBR.

  • Access to Document (DOI)

• A 5-hydroxyoxindole derivative attenuates LPS-induced inflammatory responses by activating the p38-Nrf2 signaling axis

  Niino T., Tago K., Yasuda D., Takahashi K., Mashino T., Tamura H., Funakoshi-Tago M.

  Biochemical Pharmacology （Biochemical Pharmacology)  155   182 - 197 2018年09月

  ISSN  0006-2952

  　概要を見る

  © 2018 Elsevier Inc. 5-Hydroxyoxindole is a urinary metabolite of indole that exhibits antioxidant activity. In the present study, we found that a 5-hydroxyoxindole derivative (5-HI) significantly inhibited LPS-induced inflammatory effects in the murine macrophage cell line, RAW264.7. 5-HI induced the expression of the transcription factor, Nrf2, which is typically ubiquitinated by Keap1, an adaptor component of the ubiquitin E3 ligase complex, resulting in its proteasomal degradation. By utilizing Keap1−/− MEFs reconstituted with Keap1 mutants harboring substitutions in their major cysteine residues, we clarified the importance of Cys151 in Keap1 as a sensor for 5-HI in the induction of Nrf2 expression. Furthermore, 5-HI induced the activation of the MKK3/6-p38 pathway, which is required for the transcriptional activation of Nrf2. The knockdown of Nrf2 enhanced the LPS-induced expression of inflammatory mediators, including iNOS, NO, and CCL2, and effectively repressed the inhibitory effects of 5-HI on their expression. Although 5-HI and antioxidant N-acetyl cysteine (NAC) both reduced LPS-induced ROS generation, the treatment with NAC did not affect the LPS-induced expression of inflammatory mediators, suggesting that the anti-inflammatory activity of 5-HI mediated by Nrf2 is independent of redox control. Furthermore, when injected into mice with 5-HI, the expression of Nrf2 was significantly increased, and the LPS-induced mRNA expression of CXCL1, CCL2, TNFα and IL-6 were remarkably inhibited in the kidneys, liver, and lungs, and the production of these cytokines in serum was effectively reduced. Collectively, these results suggest that 5-HI has potential in the treatment of inflammatory diseases through the activation of Nrf2.

  • Access to Document (DOI)

• Hit-to-Lead in Academia

  Yasuda Daisuke, Obata Rika, Takahashi Kyoko, Ohe Tomoyuki, Mashino Tadahiko

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 138 （ 8 ） 1059 - 1065 2018年01月

  ISSN  0031-6903

  　概要を見る

  <p> In the process of recent hit-to-lead studies, not only in industry but also in academia, early evaluation of metabolic properties has been one of the key aspects supporting a higher probability of success in drug discovery. In this review, we introduce the development of chemical seeds targeting the Kelch-like ECH-associated protein-1 (Keap1) as an example of an academic hit-to-lead study considering metabolic stability. Keap1 regulates the function of nuclear factor erythroid 2-related factor 2 (Nrf2), which induces various antioxidative or detoxification proteins. An inhibitor of protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 is expected to be a novel target for drug discovery. However, Nrf2 is also activated in several cancers, such as human hepatocellular carcinoma, and causes chemoresistance, which is mediated by phosphorylated p62/Sqstm1 (p-p62), an autophagy-related protein that also undergoes a PPI with Keap1. In this case, an Nrf2 suppressor could be used to attenuate drug resistance. We discovered inhibitors against the Nrf2-Keap1 PPI and p-p62-Keap1 PPI using high-throughput screening and established the synthetic routes for the hit compounds and their derivatives. Furthermore, we assessed the metabolic stability of both of the PPI inhibitors in human liver microsomes and identified the metabolic sites.</p>

  • Access to Document (DOI)

• Hit-to-lead in academia: Discovery of a protein-protein interaction inhibitor of Keap1-Nrf2

  Yasuda D., Obata R., Takahashi K., Ohe T., Mashino T.

  Yakugaku Zasshi （Yakugaku Zasshi)  138 （ 8 ） 1059 - 1065 2018年

  ISSN  00316903

  　概要を見る

  © 2018 The Pharmaceutical Society of Japan. In the process of recent hit-to-lead studies, not only in industry but also in academia, early evaluation of metabolic properties has been one of the key aspects supporting a higher probability of success in drug discovery. In this review, we introduce the development of chemical seeds targeting the Kelch-like ECH-associated protein-1 (Keap1) as an example of an academic hit-to-lead study considering metabolic stability. Keap1 regulates the function of nuclear factor erythroid 2-related factor 2 (Nrf2), which induces various antioxidative or detoxification proteins. An inhibitor of protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 is expected to be a novel target for drug discovery. However, Nrf2 is also activated in several cancers, such as human hepatocellular carcinoma, and causes chemoresistance, which is mediated by phosphorylated p62/Sqstm1 (p-p62), an autophagy-related protein that also undergoes a PPI with Keap1. In this case, an Nrf2 suppressor could be used to attenuate drug resistance.We discovered inhibitors against the Nrf2-Keap1 PPI and p-p62-Keap1 PPI using high-throughput screening and established the synthetic routes for the hit compounds and their derivatives. Furthermore, we assessed the metabolic stability of both of the PPI inhibitors in human liver microsomes and identified the metabolic sites.

  • Access to Document (DOI)

全件表示 >>

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

• アスコルビン酸を規範とする新規抗酸化活性化合物の創製

  高橋, 恭子

  科学研究費補助金研究成果報告書 2008年

• Synthesis of novel amino acid-type fullerenes and their inhibition activity of HIV reverse transcriptase and HCV RNA polymerase

  高橋, 恭子

  共立薬科大学雑誌 （共立薬科大学)  1   77 - 84 2006年03月

  ISSN  18805116

• Stereoselective reduction of β,δ-diketo esters derived from tartalic acid. a facile route to optically active 6-oxo-3, 5-syn-isopropylidenedioxyhexanoate, a versatile synthetic intermediate of artificial HMG Co-A reductase inhibitors

  高橋, 恭子

  共立薬科大学研究年報 （共立薬科大学)   （ 38 ） 66 - 66 1993年

  ISSN  04529731

• Role of cholesterol 10-methyl group and effect of "Extra" 14-methyl group on silkworm growth and development

  高橋, 恭子

  共立薬科大学研究年報 （共立薬科大学)   （ 34 ） 83 - 83 1989年

  ISSN  04529731

• Synthesis of 14α-methylcholesterol

  高橋, 恭子

  共立薬科大学研究年報 （共立薬科大学)   （ 32 ） 74 - 75 1987年

  ISSN  04529731

全件表示 >>

研究発表 【 表示 ／ 非表示 】

研究発表 【 表示 ／ 非表示 】

• フッ素導入により反応性代謝物の生成を回避した改良型Diclofenac類縁体の創製

  ○小川 真依、山田晶子、安田大輔、高橋恭子、中村成夫、大江知之、増野匡彦

  日本薬学会第139年会 (千葉) , 2019年03月, ポスター（一般）, 日本薬学会第139年会

• ハード及びソフトな反応性代謝物を捕捉する新規蛍光標識トラッピング剤の創製

  ○柴崎智香子、髙橋恭子、中村成夫、大江知之、増野匡彦

  日本薬学会第139年会 (千葉) , 2019年03月, 口頭（一般）, 日本薬学会第139年会

• オキシカム構造を模倣したスルホン類の抗パーキンソン病効果

  ○小町元輝、鈴木啓太、高橋恭子、中村成夫、大江知之、大久保知子、春名柚佳、田﨑嘉一、増野匡彦

  日本薬学会第139年会 (千葉) , 2019年03月, 口頭（一般）, 日本薬学会第139年会

• ハードな反応性代謝物を捕捉する新規蛍光標識化トラッピング剤の創製

  ○長邑花、柴崎智香子、髙橋恭子、中村成夫、大江知之、増野匡彦

  日本薬学会第139年会 (千葉) , 2019年03月, ポスター（一般）, 日本薬学会第139年会

• HIVプロテアーゼおよび逆転写酵素阻害活性を有する新規多標的型C60誘導体の創製：基質遷移状態模倣型イソスターとC60コアを結ぶリンカーの長さの検討

  ○古川 慶吾、髙橋恭子、中村成夫、大江知之、増野匡彦

  日本薬学会第139年会 (千葉) , 2019年03月, ポスター（一般）, 日本薬学会第139年会

全件表示 >>

担当授業科目 【 表示 ／ 非表示 】

担当授業科目 【 表示 ／ 非表示 】

• 課題研究（医薬品化学）

  2019年度

• 演習（医薬品化学）

  2019年度

• 卒業研究Ａ

  2019年度

• 高度研究機器特別演習

  2019年度

• 薬学英語演習Ａ

  2019年度

全件表示 >>